Guest: Harry Paul Erba, MD, PhD 


 For several decades, therapy for acute myeloid leukemia (AML) was rather straightforward. But now that we have a deeper understanding of the pathogenesis of AML, this has led to the identification of potential therapeutic targets that give us options in addition to standard intensive chemotherapy, as Dr. Harry Erba explains. BCL2-US-00026-MC Version 2.0, Approved November 2020

Guest: Harry Paul Erba, MD, PhD For several decades, therapy for acute myeloid leukemia (AML) was rather straightforward. But now that we have a deeper understanding of the pathogenesis of AML, this has led to the identification of potential therapeutic targets that give us options in addition to standard intensive chemotherapy, as Dr. Harry Erba explains. BCL2-US-00026-MCVersion 2.0, Approved November 2020

Guest: Harry Paul Erba, MD, PhD 


 For several decades, therapy for acute myeloid leukemia (AML) was rather straightforward. But now that we have a deeper understanding of the pathogenesis of AML, this has led to the identification of potential therapeutic targets that give us options in addition to standard intensive chemotherapy, as Dr. Harry Erba explains. BCL2-US-00026-MC Version 2.0, Approved November 2020

Therapeutic Targets in Acute Myeloid Leukemia

This unique series features the latest developments in medicine, science, and technology produced in conjunction with our sponsors, who are dedicated to bringing healthcare providers lively discussions with experts from around the country. Tune in each week to hear the latest podcasts from ReachMD's "Spotlight On" series.

Share Therapeutic Targets in Acute Myeloid Leukemia

Sign up to save your podcasts

Therapeutic Targets in Acute Myeloid Leukemia

Therapeutic Targets in Acute Myeloid Leukemia